Insmed preliminary data shows Iplex helps children grow

By Lisa Kerner

Erie, Pa., April 26 - Insmed Inc. will present preliminary data showing that rhIGF-I/rhIGFBP-3 (Iplex) administered to children with Severe Primary IGF-1 deficiency produced benefits.

The findings are from the company's prospective, multicenter clinical trial using rhIGF-I/rhIGFBP-3 (Iplex) administered once daily.

Twelve-month Height Velocity data demonstrates statistically significant, dose-dependent increases in Height Velocity with a favorable safety profile, according to data presented at the Pediatric Academic Societies' 2006 Annual Meeting in San Francisco.

Iplex is the only therapy that provides both IGF-1 and IGFBP-3 and is approved by the Food and Drug Administration to treat children with severe Primary IGFD, a genetic condition in which patients do not generate sufficient quantities of insulin-like growth factor-I (IGF-1) and insulin-like growth factor, according to the a company news release.

Insmed expects to launch the drug during the second quarter of 2006. It is also being studied in extreme insulin resistance, myotonic muscular dystrophy and HIV Associated Adipose Redistribution Syndrome.

Insmed is a Richmond, Va., biopharmaceutical company focused on the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.